{"url_path":"/sec/indp/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1857044/0001493152-26-023362-index.html","accession_number":"0001493152-26-023362","cik":"0001857044","ticker":"INDP","issuer_name":"Indaptus Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1857044/0001493152-26-023362-index.html","primary_entity_key":"0001857044","primary_entity_name":"Indaptus Therapeutics, Inc."},"word_count":89,"has_tables":true,"body_markdown":"**Item\n5. Other Information**\n\n \n\nOn April 16, 2026, Michael Newman, resigned as Chief Scientific Officer of the Company. Mr. Newman’s resignation\ndid not result from any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.\n\n \n\nDuring\nthe three months ended March 31, 2026, no director or “officer” (as defined in Rule 16a-1(f) under the Exchange Act) of the\nCompany adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as\neach term is defined in Item 408(a) of Regulation S-K."}